

# Recommendations for participation in competitive sports of athletes with arterial hypertension: a position statement from the sports cardiology section of the European Association of Preventive Cardiology (EAPC)

Josef Niebauer\*, Mats Börjesson, Francois Carre, Stefano Caselli, Paolo Palatini, Filippo Quattrini, Luis Serratos, Paolo Emilio Adami, Alessandro Biffi, Axel Pressler, Christian Schmied, Frank van Buuren, Nicole Panhuyzen-Goedkoop, Erik Solberg, Martin Halle, André La Gerche, Michael Papadakis, Sanjay Sharma, and Antonio Pelliccia

University Institute of Sports Medicine, Prevention and Rehabilitation, Paracelsus Medical University Salzburg, Lindhofstraße 20, 5020 Salzburg, Austria

Received 22 October 2017; revised 11 February 2018; editorial decision 1 August 2018; accepted 2 August 2018

Current guidelines of the European Society of Cardiology advocate regular physical activity as a Class IA recommendation for the prevention and treatment of cardiovascular disease. Despite its undisputed multitude of beneficial effects, competitive athletes with arterial hypertension may be exposed to an increased risk of cardiovascular events. This document is an update of the 2005 recommendations and will give guidance to physicians who have to decide on the risk of an athlete during sport participation.

## Keywords

Leisure time • Physical activity • Exercise training • Competition

## Introduction

Arterial hypertension is the most relevant risk factor for cardiovascular disease worldwide and one of the most common abnormalities identified during clinical evaluation of athletes.<sup>1</sup> The European Society of Cardiology (ESC) guidelines advocate regular physical activity as a Class IA recommendation for the prevention and treatment of cardiovascular disease,<sup>2</sup> which is contributing to the growing number of hypertensive individuals who train regularly and wish to engage in competitive sport.<sup>3</sup>

Arterial hypertension has been recognized as a risk factor to coronary artery disease progression and left ventricular (LV) hypertrophy, which represent substrates for myocardial infarction and ventricular arrhythmias.<sup>4</sup> Moreover, arterial hypertension induces structural changes in end-organs including the retina, kidneys, and

brain that can lead to injury and increase the risk of spontaneous haemorrhage.<sup>5</sup> Furthermore, an acute increase in blood pressure (BP) during effort may trigger atherosclerotic plaque rupture<sup>6–9</sup> leading to ischaemic myocardial or cerebrovascular events.<sup>4,6–9</sup> Therefore, timely identification of hypertensive individuals is paramount in the setting of pre-participation screening, in order to implement a healthier lifestyle, appropriate management and follow-up.<sup>10–13</sup>

For the purpose of the present position statement, our panel of experts was to propose recommendations, which represent the best possible balance between risks and benefits inherent with competitive sports participation, based on scientific evidence, when available, and consensus of experts. Detailed information on the classification, prevalence, evaluation, and recommendation for patients with arterial hypertension can be found in the current European Society of Hypertension (ESH)/ESC guidelines.<sup>5</sup>

\* Corresponding author. Tel: +43 5 7255 23200, Fax: +43 5 7255 23299, Email: j.niebauer@salk.at

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.

In this document, competitive athletes are defined as individuals of all ages, who engage in exercise training on a regular basis and participate in official sports competition, be it as amateurs or professionals.<sup>14,15</sup>

## Classification

Hypertension is defined as systolic BP  $\geq 140$  mmHg and/or diastolic BP  $\geq 90$  mmHg (Table 1), repeatedly measured in the office.<sup>16</sup> Importantly, children and adolescents have lower BP levels with normal values  $< 120/80$  mmHg.<sup>17,18</sup> In adults, the threshold for an elevated 24 h ambulatory blood pressure monitoring (ABPM) is  $\geq 130/80$  mmHg (daytime:  $\geq 135/85$  mmHg; night-time:  $\geq 120/70$  mmHg).<sup>5,16,19</sup> The cuff size should be chosen according to the circumference of the athlete's arm, and in case of asymmetric exercises (e.g. shot put, tennis, etc.) BP can be measured in the non-dominant arm.

Isolated systolic hypertension and isolated diastolic hypertension, both not rare in young men, correspond to an elevated systolic BP with normal diastolic BP or an elevated diastolic BP with normal systolic BP, respectively.

Subjects with elevated BP in the clinic and normal home blood pressure monitoring (HBPM) and/or ABPM have white-coat or isolated clinic hypertension, those with normal office BP but elevated HBPM and/or ABPM have masked hypertension.<sup>20,21</sup> Also in these conditions, thresholds given above for ABPM and HBPM apply.

During exercise, physiologically systolic BP increases and diastolic BP remains stable or mildly decreases. Even though the association between an exaggerated BP response during exercise testing and cardiovascular events is not well established, it has been related to incident hypertension.<sup>22</sup> Also, 200 mmHg at 100 W has been demonstrated to independently predict long-term mortality in healthy middle-aged men.<sup>23</sup> In Olympic, athletes systolic BP of 220 mmHg in males and 200 mmHg in females measured during cycle ergometry are beyond the 95th percentile<sup>23</sup> and thus warrant further follow-up evaluation including ABPM.<sup>24</sup>

## Prevalence

The largest study on arterial hypertension in athletes in Europe ( $n = 2000$ ; age  $25 \pm 6$  years; 64% males) reported a prevalence of 3% with only a small minority (0.2%) with secondary hypertension.<sup>25</sup>

## Evaluation

Assessment of hypertension has to be carried out in the context of other cardiovascular risk factors and resulting target organ damage like cardiovascular and/or renal complications (Table 2).<sup>16</sup> Testing for microalbuminuria after 24 h rest<sup>26</sup> and tissue Doppler imaging for plaque detection of carotid arteries may be considered in high-risk subjects. Also, clinical history, assessment of cardiovascular risk, physical examination, and subsequent diagnostic tests should be performed in order to exclude secondary causes, which may account for 5–10%, as they may be reversed with appropriate management.<sup>27</sup> Indeed, widely used supplements, energy drinks, medications (including anti-inflammatory drugs or thyroid hormones for weight reduction), or performance enhancing substances (e.g. erythropoietin, anabolic

**Table 1** Classification of blood pressure: ESH/ESC guidelines<sup>5</sup>

	Systolic		Diastolic	
Optimal	<120	and	<80	
Normal	120–129	and/or	80–84	
High normal	130–139	and/or	85–89	
Grade 1 hypertension	140–159	and/or	90–99	
Grade 2 hypertension	160–179	and/or	100–109	
Grade 3 hypertension	$\geq 180$	and/or	$\geq 110$	
Isolated systolic hypertension	$\geq 140$	and	<90	

**Table 2** Relevant clinical characteristics for risk stratification of patients with hypertension<sup>5</sup>

Risk factors	<ul style="list-style-type: none"> <li>• Men &gt;55 years; woman &gt;65 years</li> <li>• Diabetes mellitus</li> <li>• Smoking</li> <li>• Dyslipidaemia</li> <li>• Abdominal obesity</li> <li>• Premature cardiovascular disease in family (men &lt;55 years; women &lt;65 years)</li> </ul>
Target organ damage	<ul style="list-style-type: none"> <li>• LV hypertrophy induced by hypertension</li> <li>• Diastolic dysfunction</li> <li>• Ultrasound evidence of arterial wall thickening or atherosclerotic plaque</li> <li>• Hypertensive eye fundus</li> <li>• Increase in serum creatinine (men 1.3–1.5 mg/dL, women 1.2–1.4 mg/dL)</li> </ul>
Associated clinical conditions	<ul style="list-style-type: none"> <li>• Microalbuminuria</li> <li>• Atrial fibrillation</li> <li>• Cerebrovascular disease</li> <li>• Ischaemic heart disease</li> <li>• Heart failure</li> <li>• Peripheral vascular disease</li> <li>• Renal impairment, proteinuria</li> <li>• Advanced retinopathy</li> </ul>

steroids) are an underestimated cause of secondary hypertension.<sup>28,29</sup> Secondary causes of hypertension should be sought in individuals if:

- (1) Age at onset <30 years,
- (2) Absence of risk factors including family history of hypertension,
- (3) Grade 3 hypertension ( $\geq 180/110$  mmHg) or hypertensive emergencies, and
- (4) Sudden increase in BP in a previously normotensive individual or resistant hypertension despite medical treatment.<sup>27</sup>

In case of border line office measurements or in athletes with white-coat or masked hypertension, HBPM and ABPM also during training sessions should be performed.

Echocardiography has its place to assess LV hypertrophy [increased relative wall thickness (RWT) of  $> 0.42$  (RWT =

**Table 3** Stratification of total cardiovascular risk to quantify prognosis in patients with hypertension<sup>5</sup>

Other RFs, asymptomatic OD, or disease	Blood pressure (mmHg)			
	High normal SBP 130–139 or DBP 85–89	Grade 1 HT SBP 140–159 or DBP 90–99	Grade 2 HT SBP 160–179 or DBP 100–109	Grade 3 HT SBP ≥180 or DBP ≥110
No other RF		Low risk	Moderate risk	High risk
1–2 RF	Low risk	Moderate risk	Moderate to high risk	High risk
≥3 RF	Low to moderate risk	Moderate to high risk	High risk	High risk
OD, CKD Stage 3, or diabetes	Moderate to high risk	High risk	High risk	High to very high risk
CVD, CKD stage ≥4, or diabetes with OD/RFs	Very high risk	Very high risk	Very high risk	Very high risk

RF: blood pressure (high normal BP; Grades 1–3); gender, age (men ≥55 years; women ≥65 years); smoking; dyslipidaemia (total cholesterol >190 mg/dL and/or LDL >115 mg/dL and/or HDL <40 mg/dL in men and <46 mg/dL in women); fasting plasma glucose 102–125 mg/dL; abnormal glucose tolerance test; body mass index ≥30 kg/m<sup>2</sup>; abdominal obesity (men ≥102 cm; women ≥88 cm); 1st degree family history of premature cardiovascular disease (men <55 years; women <65 years). OD: hypertension-induced LV hypertrophy; carotid wall thickening or plaque; carotid-femoral pulse wave velocity >10 m/s; ankle-brachial index <0.9; CKD with eGFR 30–60 mL/min/1.73 m<sup>2</sup>; presence of micro-albuminuria. Established cardiovascular or renal disease: cerebrovascular disease; coronary heart disease; heart failure; symptomatic peripheral artery disease; CKD: eGFR <30 mL/min/1.73 m<sup>2</sup>; proteinuria; and advanced retinopathy (haemorrhages; exudates; papilloedema).

CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; HT, hypertension; OD, organ damage; RF, risk factor; SBP, systolic blood pressure.

**Table 4** General recommendations for competitive sport participation in athletes with systemic hypertension


Criteria for eligibility	Recommendations	Evaluation	Follow-up
BP: well controlled Further RF: none TOD: none ACC: none	All sports	History, PE, ECG, ET; echo <sup>a</sup>	Yearly
BP: well controlled Further RF: well controlled TOD: none ACC: none	All sports	History, PE, ECG, ET; echo	6–12 months
BP: well controlled Further RF: well controlled TOD: present ACC: none	All sports, except power sports known to severely increase BP	History, PE, ECG, ET; echo	6 months
BP: well controlled Further RF: well controlled TOD: none or present ACC: present	All sports, except power sports known to severely increase BP <sup>b</sup>	History, PE, ECG, ET; echo	6 months

Individual recommendations need to also consider cardiovascular risk profile, target organ damage and associated clinical conditions.

ACC, associated clinical condition; BP, blood pressure; ET, exercise testing; LVH, left ventricular hypertrophy; PE, physical examination, including BP measurements<sup>5</sup>; RF, risk factors; TOD, target organ damage.

<sup>a</sup>Echocardiography according to clinical condition, but once every 1–2 years.

<sup>b</sup>Eligibility depending on type and severity of ACC and/or TOD.



**Figure 1** Pre-participation examination in competitive athletes with arterial hypertension. Evaluation includes family and personal history, cardiovascular risk profile, physical examination, blood pressure, and resting 12-lead ECG. Additional tests according to current guidelines. If blood pressure is <140/90 mmHg (<140/85 mmHg in diabetic), all competitive sports are allowed. Otherwise, no competitive sports until normalization of values. Depending on associated clinical conditions and/or target organ damage restrictions may apply (Table 4).

interventricular septum + posterior wall/end-diastolic diameter)] and mass (>110 g/m<sup>2</sup> in men, >95 g/m<sup>2</sup> in women),<sup>30</sup> impaired relaxation (measured by tissue Doppler echocardiography) or systolic dysfunction (assessed by longitudinal strain analysis),<sup>31–34</sup> valves, and the ascending aorta.

Long-term, high-volume, and high-intensity endurance sport itself may induce enlargement of all cardiac cavities and mild LV hypertrophy, better known as athlete's heart. Whereas these physiological adaptations are reversible by detraining,<sup>35</sup> remodeling caused by hypertension is not, but is amenable to effective BP lowering therapy.

Exercise testing (with ECG and BP monitoring)<sup>25</sup> should be routinely performed to assess exercise capacity and to rule out exercise-induced hypertension. As stated above, BP values obtained during exercise should not be used for a definitive diagnosis of hypertension,<sup>36</sup> since it is uncertain whether it is a reliable predictor of overt arterial hypertension later in life.<sup>24,37–39</sup> Nonetheless, at least annual follow-up preferably with

ABPM and particular attention to cardiovascular risk factors is warranted, but without restriction from any competitive sport.<sup>23</sup>


### Risk stratification

The terms low-, moderate-, high-, and very high-risk correspond to approximate absolute 10-year risks of cardiovascular mortality of <1%, 1–4%, 5–10%, and >10%, respectively, according to the European SCORE system as defined by the 2016 ESC prevention guidelines.<sup>2</sup>

## Recommendations

### General recommendations

Athletes with hypertension should be treated according to general guidelines.<sup>27</sup> Appropriate non-pharmacological measures should be considered as the first step: salt restriction, weight reduction when obesity is present, alcohol restriction, increased consumption of vegetables and fruits, smoking cessation, discontinuation of supplements, ergogenic, and/or anti-inflammatory drugs. Aerobic-exercise



programmes should complement athletes' training schedules. (Level of evidence: IB).

Athletes should be periodically reassessed and in case of low or moderate risk, drug treatment is initiated when hypertension persists, e.g. 3 months after appropriate lifestyle changes have been implemented or when out-of-office BP remains elevated. It is not recommended to initiate antihypertensive therapy at high normal BP, however, lifestyle changes are encouraged. Antihypertensive drug therapy should be started promptly in athletes with Grade 3 hypertension and/or high- or very high risk for cardiovascular complications (Table 3). (Level of evidence: IB).

The goal of antihypertensive therapy is to reduce BP to <140/90 mmHg and to <140/85 mmHg in diabetic athletes,<sup>5</sup> although the current trend is to adopt lower values, i.e. <130/80, as recently advocated in the ACC/AHA guidelines.<sup>40</sup> (Level of evidence: IB).

With regard to white-coat or masked hypertension, ABPM may be particularly useful in assessing BP load. With regard to antihypertensive drugs, current evidence indicates that they are not required. In the absence of randomized trials, it will remain an individual decision to prescribe antihypertensive drugs even in patients with high- or very high cardiovascular risk (Table 3). In any case, regular follow-up and non-pharmacological measures are recommended.<sup>27</sup> Also, since it remains uncertain whether isolated systolic or isolated diastolic hypertension progress to overt hypertension or benefit from drug treatment, only lifestyle changes are warranted. (Level of evidence: IB).


### Choice of drugs

Athletes who compete at national and/or international level have to review the current list of prohibited substances and methods of the World Anti-Doping Association<sup>41</sup> before starting drug therapy. If required, a therapeutic use exemption has to be obtained in order to receive the authorization to take the needed medicine.

Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are the preferred choice as they do not affect exercise capacity and are not on the doping list. However, they shall not be given to females during reproductive years, because of potential adverse foetal/neonatal effects.

Alternatively or additionally calcium channel blockers are a preferred choice in athletes. If more than one drug is required, combination drugs should be considered as they may improve compliance. Beta blockers are rarely used as second line therapy, as they can generally not be given in athletes with bradycardia <50/min and/or second or third degree AV block. Furthermore, different beta blockers (selective/non selective, older/newer compounds, with/without vasodilatory properties) negatively impact aerobic-exercise performance, which may interfere with compliance. Also, beta blockers are prohibited and considered as doping in some sports like archery and shooting where control of tremor is sought.<sup>16,42</sup>

Diuretics are banned at all times and in all sports, since they may mask performance-enhancing drugs.<sup>43,44</sup>



### Recommendations for competitive sports participation

Recommendations are based on risk stratification and with the understanding that the clinical condition is stable and that general recommendations for the management of hypertension are observed as described above (Table 4).

1. In patients with low- or moderate-cardiovascular risk, usually no restrictions apply. If BP values are not normalized, temporary restriction from competitive sport is recommended, with possible exception of skill disciplines (Figures 1 and 2).

2. In patients with high-risk or very high-risk in whom control of BP has been achieved, participation in all competitive sports is possible,

with the exception of power disciplines (Figures 1 and 2). If BP values are not well controlled, temporary restriction from competitive sport is recommended.

### Leisure-time and amateur sport activities

Regular exercise training has been shown to reduce morbidity and mortality<sup>47</sup> and is thus a Class IA indication.<sup>2</sup> Patients are advised to perform at least 30 min of moderate-intensity, preferably (but not exclusively) aerobic-exercise training, 5–7 days per week.<sup>5</sup> In patients



with low- or moderate cardiovascular risk high-intensity exercises can be performed,<sup>48</sup> even if common but arbitrary cut-offs, e.g. systolic BP  $\geq 240$  mmHg, are exceeded during peak intervals.

## Follow-up

Patients need to be followed up regularly by their physicians. In addition, during annual pre-competition medical examination BP needs to be measured at rest and during exercise testing. Furthermore, possible reversal or progression of existing target organ damage has to be assessed by ECG, echocardiography, kidney testing, and/or retinal examination.

An ACC/AHA statement<sup>9</sup> recommends athletes with hypertension who wish to engage in training for competitive sports to undergo prior clinical assessment including BP, which is in keeping with this position statement and our ESC consensus statement.<sup>49</sup>

## Summary

The prevalence of arterial hypertension is high overall, increasing with age and unfavourably influenced by western diet and behaviour even in athletes. Therefore, screening should also focus on adolescent athletes. Special considerations have to be given regarding the pharmacological treatment of hypertension in athletes. While eligibility for competitive sports may have to be restricted if target organ damage is present, an athlete with well-controlled BP, having no additional risk factors or target organ damage, is eligible for competition in all sports.

**Conflict of interest:** A.Pr., E.S., J.N., M.B., M.H., and M.P. have disclosed fees for lectures, advisory boards and/or research. And all other authors have nothing to disclose.

## References

- Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. *Circulation* 2016;**134**:441–450.
- Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FD, Lochan ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WM. 2016 European guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J* 2016;**37**:2315–2381.
- Fagard RH. Athletes with systemic hypertension. *Cardiol Clin* 2007;**25**:441–448, vii.
- Rodriguez CJ, Sacco RL, Sciacca RR, Boden-Albala B, Homma S, Di Tullio MR. Physical activity attenuates the effect of increased left ventricular mass on the risk of ischemic stroke: the Northern Manhattan Stroke Study. *J Am Coll Cardiol* 2002;**39**:1482–1488.
- Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Burnier M, Ambrosioni E, Caulfield M, Coca A, Olsen MH, Tsoufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Ferrari R, Hasdai D, Hoes AW, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Gillebert TC, Rosei EA, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Ryden L, Sirenko Y, Stanton A, Struijker-Boudier H, Vlachopoulos C, Volpe M, Wood DA. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J* 2013;**34**:2159–2219.
- Laukkanen JA, Khan H, Kurl S, Willeit P, Karppi J, Ronkainen K, Di Angelantonio E. Left ventricular mass and the risk of sudden cardiac death: a population-based study. *J Am Heart Assoc* 2014;**3**:e001285.
- Laukkanen JA, Jennings JR, Kauhanen J, Makikallio TH, Ronkainen K, Kurl S. Relation of systemic blood pressure to sudden cardiac death. *Am J Cardiol* 2012;**110**:378–382.
- Okin PM, Bang CN, Wachtell K, Hille DA, Kjeldsen SE, Dahlof B, Devereux RB. Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. *Circ Arrhythm Electrophysiol* 2013;**6**:243–251.
- Black HR, Sica D, Ferdinand K, White WB. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 6: hypertension: a Scientific Statement from the American Heart Association and the American College of Cardiology. *Circulation* 2015;**132**:e298–e302.
- Selden MA, Helzberg JH, Waeckerle JF. Early cardiovascular mortality in professional football players: fact or fiction? *Am J Med* 2009;**122**:811–814.
- Baron SL, Hein MJ, Lehman E, Geric CM. Body mass index, playing position, race, and the cardiovascular mortality of retired professional football players. *Am J Cardiol* 2012;**109**:889–896.
- Hurst RT, Burke RF, Wissner E, Roberts A, Kendall CB, Lester SJ, Somers V, Goldman ME, Wu Q, Khandheria B. Incidence of subclinical atherosclerosis as a marker of cardiovascular risk in retired professional football players. *Am J Cardiol* 2010;**105**:1107–1111.
- Sundstrom J, Neovius M, Tynelius P, Rasmussen F. Association of blood pressure in late adolescence with subsequent mortality: cohort study of Swedish male conscripts. *BMJ* 2011;**342**:d643.
- Pelliccia A, Fagard R, Bjørnstad HH, Anastassakis A, Arbustini E, Assanelli D, Biffi A, Borjesson M, Carrè F, Corrado D, Delise P, Dorwarth U, Hirth A, Heidbuchel H, Hoffmann E, Mellwig KP, Panhuyzen-Goedkoop N, Pisani A, Solberg EE, van-Buuren F, Vanhees L, Blomstrom-Lundqvist C, Deligiannis A, Dugmore D, Glikson M, Hoff PI, Hoffmann A, Hoffmann E, Horstkotte D, Nordrehaug JE, Oudhof J, McKenna WJ, Penco M, Priori S, Reybrouck T, Senden J, Spataro A, Thiene G. Recommendations for competitive sports participation in athletes with cardiovascular disease. *Eur Heart J* 2005;**26**:1422–1445.
- Solberg EE, Borjesson M, Sharma S, Papadakis M, Wilhelm M, Drezner JA, Harmon KG, Alonso JM, Heidbuchel H, Dugmore D, Panhuyzen-Goedkoop NM, Mellwig KP, Carre F, Rasmusen H, Niebauer J, Behr ER, Thiene G, Sheppard MN, Basso C, Corrado D. Sudden cardiac arrest in sports—need for uniform registration: a Position Paper from the Sport Cardiology Section of the European Association for Cardiovascular Prevention and Rehabilitation. *Eur J Prev Cardiol* 2016;**23**:657–667.
- O'Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, Clement D, de la Sierra A, de Leeuw P, Dolan E, Fagard R, Graves J, Head GA, Imai Y, Kario K, Lurbe E, Mallion J-M, Mancia G, Mengden T, Myers M, Ogedegbe G, Ohkubo T, Omboni S, Palatini P, Redon J, Ruilope LM, Shennan A, Staessen JA, vanMontfrans G, Verdecchia P, Waeber B, Wang J, Zanchetti A, Zhang Y. European Society of Hypertension position paper on ambulatory blood pressure monitoring. *J Hypertens* 2013;**31**:1731–1768.
- Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B, Flinn SK, Gidding SS, Goodwin C, Leu MG, Powers ME, Rea C, Samuels J, Simasek M, Thaker VV, Urbina EM. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. *Pediatrics* 2017;**140**:e20171904.
- Lurbe E, Agabiti-Rosei E, Cruickshank JK, Dominiczak A, Erdine S, Hirth A, Invitti C, Litwin M, Mancia G, Pall D, Rascher W, Redon J, Schaefer F, Seeman T, Sinha M, Stabouli S, Webb NJ, Wühl E, Zanchetti A. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. *J Hypertens* 2016;**34**:1887–1920.
- Parati G, Stergiou G, O'Brien E, Asmar R, Beilin L, Bilo G, Clement D, de la Sierra A, de Leeuw P, Dolan E, Fagard R, Graves J, Head GA, Imai Y, Kario K, Lurbe E, Mallion J-M, Mancia G, Mengden T, Myers M, Ogedegbe G, Ohkubo T, Omboni S, Palatini P, Redon J, Ruilope LM, Shennan A, Staessen JA, vanMontfrans G, Verdecchia P, Waeber B, Wang J, Zanchetti A, Zhang Y. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. *J Hypertens* 2014;**32**:1359–1366.
- Jardim TV, de Souza Carneiro C, Morais P, Mendonca KL, Povoas TIR, Nascente FM, Roriz V, Barroso WKS, Sousa ALL, Jardim PCV. Home blood pressure normalcy in non-European adolescents. *J Hypertens* 2018;**36**:61–68.
- Le VV, Mitiku T, Sungar G, Myers J, Froelicher V. The blood pressure response to dynamic exercise testing: a systematic review. *Prog Cardiovasc Dis* 2008;**51**:135–160.

22. Schultz MG, La Gerche A, Sharman JE. Blood pressure response to exercise and cardiovascular disease. *Curr Hypertens Rep* 2017;**19**:89.
23. Caselli S, Vaquer Segui A, Quattrini F, Di Gacinto B, Milan A, Assorgi R, Verdile L, Spataro A, Pelliccia A. Upper normal values of blood pressure response to exercise in Olympic athletes. *Am Heart J* 2016;**177**:120–128.
24. Kjeldsen SE, Mundal R, Sandvik L, Erikssen G, Thaulow E, Erikssen J. Supine and exercise systolic blood pressure predict cardiovascular death in middle-aged men. *J Hypertens* 2001;**19**:1343–1348.
25. Caselli S, Vaquer Segui A, Lemme E, Quattrini F, Milan A, D'Ascenzi F, Spataro A, Pelliccia A. Prevalence and management of systemic hypertension in athletes. *Am J Cardiol* 2017;**119**:1616–1622.
26. Mosconi G, Angelini ML, Balzi W, Totti V, Roi GS, Cappuccilli M, Tonioli M, Storani D, Trerotola M, Costa AN. Can solid-organ-transplanted patients perform a cycling marathon? Trends in kidney function parameters in comparison with healthy subjects. *Transplant Proc* 2016;**48**:415–419.
27. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? *Eur Heart J* 2014;**35**:1245–1254.
28. Leddy JJ, Izzo J. Hypertension in athletes. *J Clin Hypertens (Greenwich)* 2009;**11**:226–233.
29. Achar S, Rostamian A, Narayan SM. Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. *Am J Cardiol* 2010;**106**:893–901.
30. Baggish AL, Weiner RB, Yared K, Wang F, Kupperman E, Hutter AM Jr, Picard MH, Wood MJ. Impact of family hypertension history on exercise-induced cardiac remodeling. *Am J Cardiol* 2009;**104**:101–106.
31. Caselli S, Montesanti D, Autore C, Di Paolo FM, Picchio C, Squeo MR, Musumeci B, Spataro A, Pandian NG, Pelliccia A. Patterns of left ventricular longitudinal strain and strain rate in Olympic athletes. *J Am Soc Echocardiogr* 2015;**28**:245–253.
32. Caselli S, Di Paolo FM, Picchio C, Pandian NG, Pelliccia A. Patterns of left ventricular diastolic function in Olympic athletes. *J Am Soc Echocardiogr* 2015;**28**:236–244.
33. Galderisi M, Lomoriello VS, Santoro A, Esposito R, Olibet M, Raia R, Di Minno MN, Guerra G, Mele D, Lombardi G. Differences of myocardial systolic deformation and correlates of diastolic function in competitive rowers and young hypertensives: a speckle-tracking echocardiography study. *J Am Soc Echocardiogr* 2010;**23**:1190–1198.
34. Lin J, Wang F, Weiner RB, DeLuca JR, Wasfy MM, Berkstresser B, Lewis GD, Hutter AM Jr, Picard MH, Baggish AL. Blood pressure and LV remodeling among American-style football players. *JACC Cardiovasc Imaging* 2016;**9**:1367–1376.
35. Pluim BM, Zwinderman AH, van der Laarse A, van der Wall EE. The athlete's heart. A meta-analysis of cardiac structure and function. *Circulation* 2000;**101**:336–344.
36. Kjeldsen S, Feldman RD, Lisheng L, Mourad JJ, Chiang CE, Zhang W, Wu Z, Li W, Williams B. Updated national and international hypertension guidelines: a review of current recommendations. *Drugs* 2014;**74**:2033–2051.
37. Smith RG, Rubin SA, Ellestad MH. Exercise hypertension: an adverse prognosis? *J Am Soc Hypertens* 2009;**3**:366–373.
38. Weiss SA, Blumenthal RS, Sharrett AR, Redberg RF, Mora S. Exercise blood pressure and future cardiovascular death in asymptomatic individuals. *Circulation* 2010;**121**:2109–2116.
39. Schultz MG, Otahal P, Cleland VJ, Blizzard L, Marwick TH, Sharman JE. Exercise-induced hypertension, cardiovascular events, and mortality in patients undergoing exercise stress testing: a systematic review and meta-analysis. *Am J Hypertens* 2013;**26**:357–366.
40. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbigele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. *J Am Coll Cardiol* 2017;**71**:e127–e248.
41. [https://www.wada-ama.org/sites/default/files/prohibited\\_list\\_2018\\_en.pdf](https://www.wada-ama.org/sites/default/files/prohibited_list_2018_en.pdf) (14 August 2018).
42. Pescatello LS, Franklin BA, Fagard R, Farquhar WB, Kelley GA, Ray CA. American College of Sports Medicine position stand. Exercise and hypertension. *Med Sci Sports Exerc* 2004;**36**:533–553.
43. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002;**288**:2981–2997.
44. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Oggedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA* 2014;**311**:507.
45. Pelliccia A, Adami PE, Quattrini F, Squeo MR, Caselli S, Verdile L, Maestrini V, Di Paolo F, Picchio C, Ciardo R, Spataro A. Are Olympic athletes free from cardiovascular diseases? Systematic investigation in 2352 participants from Athens 2004 to Sochi 2014. *Br J Sports Med* 2017;**51**:238–243.
46. Pelliccia A, Quattrini FM, Squeo MR, Caselli S, Culasso F, Link MS, Spataro A, Bernardi M. Cardiovascular diseases in Paralympic athletes. *Br J Sports Med* 2016;**50**:1075–1080.
47. Naci H, Ioannidis JP. Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. *Br J Sports Med* 2015;**49**:1414–1422.
48. Howden EJ, Sarma S, Lawley JS, Opondo M, Cornwell W, Stoller D, Urey MA, Adams-Huet B, Levine BD. Reversing the cardiac effects of sedentary aging in middle age—a randomized controlled trial: implications for heart failure prevention. *Circulation* 2018;**137**:1549–1560.
49. Corrado D, Pelliccia A, Bjornstad HH, Vanhees L, Biffi A, Borjesson M, Panhuyzen-Goedkoop N, Deligiannis A, Solberg E, Dugmore D, Mellwig KP, Assanelli D, Delise P, van-Buuren F, Anastakis A, Heidbuchel H, Hoffmann E, Fagard R, Priori SG, Basso C, Arbustini E, Blomstrom-Lundqvist C, McKenna WJ, Thiene G. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death. *Eur Heart J* 2005;**26**:516–524.